We have shown that treatment with interleukin-2 (IL-2) or interferon-␣ (IFN␣) may induce depressive symptoms and activation of the cytokine network and that IL-2 treatment may diminish serum dipeptidyl pepdidase IV (DPP IV) activity.
Immunotherapy with interleukin-2 (IL-2) and interferon-␣ (IFN␣) has become standard therapy in (selected) patients with hepatitis or kidney carcinoma. Immunotherapy with IL-2 (with and without IFN␣) frequently induces depressive symptoms and full blown major depression within the first few days after starting treatment. 1 IL-2 based immunotherapy induces the cytokine network, 1 eg it elevates serum interleukin-6 (IL-6) and soluble IL-2 receptor (IL-2R) concentrations. 1 Activation of the inflammatory response system (IRS) and administration of proinflammatory cytokines, such as IL-1 and IL-6, may induce depressogenic effects in experimental animals and humans. [8] [9] [10] [11] For example, in mice, sustained increases in serum IL-6 induces a rapid decline in preference for sucrose. 11 Therefore, we have hypothesized that IRS activation could play a role in the etiology of IL-2-induced depression. 1 Long-term IFN␣-based immunotherapy (several weeks) induces depression in a considerable number of patients. 2, 3 The IFN␣-induced increases in depression ratings are significantly related to IFN␣-induced changes in the serotonergic system, such as reductions in serum serotonin (5-HT) and plasma tryptophan, the precursor of 5-HT, and increases in serum kynurenine, the major tryptophan metabolite. 2 The etiopathology of 'endogenous' (non-organic) depression may in part be related to disorders in the peripheral and central metabolism of 5-HT, such as lowered activity of the central presynaptic serotonergic neurons, a lowered availability of plasma tryptophan, and to changes in postsynaptic serotonergic receptors. 12 Therefore, we have suggested that the IFN␣-based immunotherapyinduced changes in the serotonergic system may play a role in the development of IFN␣-induced depressive symptoms. 2 Changes in other neurotransmitters, however, are undoubtedly involved in the etiopathology of depression. 'Endogenous' depression is also characterized by IRS activation as indicated by increased production of pro-inflammatory cytokines, such as IL-1␤, IL-6 and IFN␥. 8 Changes in the serotonergic system in 'endogenous' depression, such as reduced plasma tryptophan, are related to signs of IRS activation. 8, 13 'Endogenous' and IL-2-induced depression and conditions characterized by IRS activation, such as inflammatory and autoimmune disorders (rheumatoid arthritis, autoimmune chronic hepatitis and systemic lupus erythematosus) are accompanied by lowered serum activity of dipeptidyl peptidase IV (DPP IV; EC 3.4.14.5).
14-16 DPP IV is a membrane-bound serine pro-tease that catalyses the cleavage of dipeptides from the amino-terminus of oligo-and polypeptides under definite structural conditions. 4 On the T cell surface, DPP IV has proven to be identical with the CD26 molecule and its expression is increased-together with that of other activation markers. 17 A suppressed activity of DPP IV may have psychoneuroimmune consequences, since some cytokines, chemokines and neuroactive peptides are potential substrates of DPP IV, eg IL-1␤, IL-6, substance P, growth hormone releasing hormone, neuropeptide Y, and peptide YY.
18,19 IL-2-based immunotherapy for 3-5 days significantly suppresses serum DPP IV activity. 1 The aims of the present study are to examine whether: (1) therapy with IFN␣ in patients with hepatitis C suppresses serum DPP IV activity; and (2) the immunotherapy-induced reductions in serum DPP IV activity are inversely related to the development of depressive symptomatology and to signs of IRS activation. Table 1 shows the MADRS, HAM-A and serum DPP IV values in baseline conditions and during IFN␣-based immunotherapy. Figure 1 shows the MADRS scores in the hepatitis-C patients both before and during therapy with IFN␣. Patients are divided into those with increases of more than 9 points on the MADRS from baseline to 4-6 months later and those without such an increase. Repeated measurement (RM) design analysis of variance (ANOVA) showed a significant effect of time (F = 7.5, df = 1/16, P = 0.04) and a significant time × MADRS status interaction (F = 7.4, df = 1/16, P = 0.01). Analyses of simple effects showed: (1) significant effects of time in patients who showed an increase of more than 9 points in the MADRS from baseline to 4-6 months later (F = 9.9, P = 0.001), but not in those without such an increase (F = 2.0, P = 0.2); and (2) a significantly higher MADRS score in patients who showed an increase in the MADRS than in those without, 4-6 months (F = 10.4, P = 0.003) but not 2-4 , and 2-4 weeks and 4-6 months after starting immunotherapy. The patients were divided into those whose MADRS scores increased more than 9 points from baseline to endpoint (MADRS Ͼ 9) and those whose MADRS scores remained low during treatment (MADRS Ͻ 9) or into those whose HAM-A scores increased more than 6 points from baseline to endpoint (HAM-A Ͼ 6) and those whose MADRS scores remained low during treatment (HAM-A Ͻ 6).
weeks after starting treatment (F = 0.7, P = 0.6) and not in the baseline condition (F = 0.8, P = 0.6). Figure 1 shows the HAM-A score in patients with an increase of more than 6 points on the HAM-A from baseline to 4-6 months later and in patients without such an increase. RM design ANOVA showed a significant effect of time (F = 4.7, df = 1/14, P = 0.04) and a significant time × group interaction (F = 3.5, df = 1/14, P = 0.05). Analyses of simple effects showed a significant effect of IFN␣ on the HAM-A score in patients with an increase of more than 6 points on the HAM-A (F = 8.2, P = 0.002), but not in those without such an increase (F = 0.9, P = 0.6). Dunn tests showed significantly higher HAM-A scores 2-4 weeks (t = 2.66, P = 0.01) and 4-6 months (t = 2.66, P = 0.01) after starting IFN␣-based immunotherapy than in baseline conditions. Figure 1 shows serum DPP IV values in hepatitis C patients, divided in patients who showed or did not show an increase of more than 9 points in the MADRS from baseline to 4-6 months later. ANOVA showed a significantly lower serum DPP IV activity in patients who showed an increase of more than 9 points in the MADRS than in those without such changes (F = 4.5, df = 1/36, P = 0.039). RM design ANOVA performed on the DPP IV values with the MADRS status as group factor, showed a significant effect of time (F = 42.7, df = 2/21, P Ͻ 10 −4 ) but no significant time × group interaction (F = 0.3, df = 2/21, P = 0.7). Analyses on simple effects showed a significant effect of time in patients who showed an increase of more than 9 points in the MADRS (F = 18.4, df = 2/24, P Ͻ 10 −4 ) and in those who did not (F = 24.6, df = 2/24, P Ͻ 10 −4 ). Dunn tests showed significantly lower serum DPP IV values 2-4 weeks (t = 5.98, P Ͻ 10
) and 4-6 months (t = 9.20, P Ͻ 10 −4 ) after starting IFN␣ therapy than in baseline conditions and significantly lower serum DPP IV values 4-6 months after starting treatment than after 2-4 weeks (t = 3.23, P = 0.004). A RM design ANOVA with DPP IV as dependent variable and HAM-A status as grouping variable showed a significant effect of time (F = 63.3, df = 2/23, P Ͻ 10 −4 ) and a trend toward a significant time × group interaction (F = 3.0, df = 2/23, P = 0.07). ANOVA with gender as factor showed significantly lower serum DPP IV activity in women (mean = 31.2 ± 6.6 U l −1 ) than in men (mean = 38.0 ± 11.1 U l −1 ). RM design ANOVA with gender as factor showed no significant gender × time interaction (F = 0.3, df = 2/21, P = 0.7). Analysis on simple effects showed significant suppressant effects of immunotherapy with IFN␣ on serum DPP IV in women (F = 18.3, df = 2/24, P Ͻ 10
) and in men (F = 24.5, df = 2/24, P Ͻ 10
−4
). There were no significant correlations between age and serum DPP IV at baseline (r = −0.38, P = 0.2), 2-4 weeks after starting treatment (r = −0.36, P = 0.2) and 4-6 weeks later (r = −0.32, P = 0.3).
Regression analyses, pooled over the subjects (intraclass correlations) and taking into account the three time points, showed significant time-relationships between the changes over time between serum DPP IV and the MADRS (r = −0.47, F = 7.7, df = 1/27, P = 0.009) and the HAM-A score (r = −0.52, F = 10.1, df = 1/27, P Molecular Psychiatry = 0.004). Figure 1 , however, shows that serum DPP IV activity decreases in patients who have or have not increases in their MADRS scores of more than 9 points from baseline to endpoint. This suggests that the depression scores and DPP IV activity may be independent of one another. However, also using change scores, ie the ⌬ values = endpoint (4-6 months) minus the baseline values, we found a significant and inverse relationship between the ⌬ MADRS and ⌬ DPP IV values (r = −0.76, P = 0.003, n = 14; intra-class correlation pooled over the two patient groups divided according to their MADRS responses to IFN␣-based immunotherapy).
In order to examine the relationships between the changes over time in serum DPP IV and IRS activation we examined the correlations between the changes over time in serum DPP IV, on the one hand, and serum IL-8 and the K/T quotient, on the other (intra-class correlations pooled over the subjects). Table 1 shows the IL-8 and the K/T values. RM design ANOVA performed on the IL-8 values showed a significant effect of time (F = 5.2, df = 2/21, P = 0.01). Dunn tests showed significantly higher serum IL-8 2-4 weeks after starting immunotherapy than at baseline (t = 3.70, P = 0.004) and no significant differences between baseline and 4-6 months later (t = 1.12, P = 0.2). Regression analyses pooled over the subjects (intra-class correlation) showed significant time-relationships between the IFN␣-induced changes in serum DPP IV and IL-8 (r = −0.42, P = 0.02). RM design ANOVA showed a significant enhancing effect of IFN␣-based immunotherapy on the K/T ratio (F = 41.3, df = 2/19, P Ͻ 10 −4 ), but no significant time × MADRS status effect (F = 1.4, df = 2/19, P = 0.3). Dunn tests showed a significantly higher K/T quotient 2-4 weeks (t = 5.54, P Ͻ 10 −4 and 4-6 months (t = 9.11, P Ͻ 10 −4 ) after starting IFN␣ treatment and a significantly higher K/T quotient 4-6 months after treatment than at 2-4 weeks (t = 3.58, P = 0.002). There was a significant negative correlation between the changes over time in serum DPP IV and the K/T quotient (r = −0.75, F = 34.3, df = 1/27, P Ͻ 10 −4 ; regression analysis pooled over the subjects).
To the best of our knowledge, this is a first study reporting that long-term (2 weeks-6 months) IFN␣-based immunotherapy significantly suppresses serum DPP IV activity in patients with hepatitis C. Previously, we have shown that treatment with IL-2 (with or without IFN␣), but not IFN␣ alone, for 3-5 days significantly suppressed serum DPP IV activity. 1 Thus, it appears that short-term immunotherapy with IFN␣ (Ͻ 5 days) does not affect DDP IV activity, whereas longer term therapy (Ͼ2 weeks) results in significant effects. The mechanisms whereby IFN␣-based immunotherapy may decrease serum DPP IV activity have remained elusive. It has been shown that IFN␣ may increase DPP IV/CD26 mRNA expression in renal tubular epithelial cells and renal cell carcinoma cells in culture. 20 Other cytokines, however, whose production may be induced by IFNs, such as tumor necrosis factor-␣ (TNF␣) and TGF␤, may reduce DPP IV mRNA and enzyme activity. 20, 21 A second major finding of this study is the significant and inverse relationship between the IFN␣-induced increases in the MADRS and HAM-A scores and the decreases in DPP IV activity and the significantly lower serum DPP IV activity in patients who have a marked increase in the MADRS as compared to those without such an increase. These findings extend those of previous papers showing that 'endogenous' major depression is accompanied by lowered serum DPP IV activity and that the IL-2-induced decreases in serum DPP IV are significantly and inversely correlated with the increases in the MADRS.
1 IFN␣-based immunotherapy is known to induce depressive and anxiety symptoms and full blown major depression in a number of patients.
2,3 IFN␣-based immunotherapy has depressogenic properties through different mechanisms. First, it induces the production of pro-inflammatory cytokines, such as IL-6, which have depressogenic activities. Second, IFN␣ affects the serotonergic system and increases 5-HT transporter mRNA and uptake activity;
22 suppresses 5-HT concentrations in brain or serum; 23 and induces the catabolism of tryptophan to kynurenine, probably through induction of the IDO pathway by interferons. 24 Third, activation of the hypothalamic-pituitary-adrenal (HPA) axis is a common feature of depression 13 and occurs following IFN␣-based immunotherapy. 25 Previously, it was shown that circulating IL-6 increases after systemic IFN␣ administration, resulting in activation of the HPA-axis. 25 In the present study, however, we did not measure the HPAaxis hormones.
The third major finding of this study is that the IFN␣-induced decrements in serum DPP IV activity are significantly and inversely related to indicants of IFN␣-induced IRS activation, ie increased serum IL-8 and K/T quotient. IL-8 is produced by monocytes, macrophages, neutrophils and endothelial cells after stimulation by IL-1 and TNF␣ and it induces the chemotaxic activity of immune cells. 26 An increased K/T quotient indicates an increased catabolism, of tryptophan probably through IFN␣-induced IDO. 7 IFN␥ and IFN␣ may induce IDO in the brain, kidney, lung, spleen, duodenum and immune cells. 24, 27 Our findings extend previous results showing that inflammatory conditions and disorders are accompanied by lower serum DPP IV activity [14] [15] [16] 28 and that in depression lowered serum DPP IV is related to signs of IRS activation.
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Materials and methods
Subjects
Eighteen chronic active hepatitis C patients participated in this study. There were 10 men and 8 women with a mean age (± SD) of 40.5 (± 11.5) years. The patients were recruited at the Hepatology Department, I Medical Clinic at the University of Rome 'La Sapienza' between November 1997 and May 1998. Three of the patients stopped treatment after a few days: one due to a reduction in the number of platelets and two because of IFN␣ low compliance. In one patient, the baseline measurements of serum DPP IV and plasma IL-8 were missing. Finally, 14 hepatitis C patients completed the IFN␣ treatment, the psychiatric assessments and the blood samplings, ie eight men and six women with a mean age (± SD) of 41.7 (± 10.8) years. Inclusion criteria were: (1) a diagnosis of chronic active hepatitis C, which was based on persistently elevated transminase values (1.5 over the normal range for at least 6 months), anti-HCV positivity and histological report; (2) age Ͻ65 years; (3) histological diagnosis of chronic hepatitis; (4) positivity for anti-HCV antibodies and HCV RNA in serum; and (5) platelet counts Ͼ100.000 mm −3 . The exclusion criteria for patients were: (1) patients with liver cirrhosis, heart, kidney or autoimmune diseases; (2) infection with HBV, HDV or HIV; (3) WBC counts Ͻ4000 mm −3 ; (4) a PT Ͻ 60%; (5) chronic alcohol abuse or active intravenous drug use (IVDU); and (6) patients with a past or present history of axis-I disorders, such as major and bipolar depression. None of the patients was taking any psychotropic drugs for at least 1 year prior to IFN␣-based immunotherapy. None of the patients took any other medication besides IFN␣, including antidepressants, during the study period. No changes in physical status were recorded during the treatment period. Illness onset and awareness ranged from a minimum of 1 to a maximum of 2 years. The local ethical committee approved the study design and the subjects gave written informed consent after the study protocol was fully explained.
Methods
The hepatitis C patients were randomized to receive two IFN␣2 (Roferon, Roche, Switzerland) treatment schedules: the first with 6 MU IFN␣ s.c. per day, 6 days a week for 4 weeks; the second with 6 MU IFN s.c. three times a week for 4 weeks. There were no significant differences at any of the time points in the clinical ratings, serum DPP IV activity, serum IL-8 or the K/T quotient between these two time points. Therefore, subsequent statistical analyses were performed on both treatment groups combined. After the initial 4-week treatment period, all patients continued IFN␣ therapy with 6 MU IFN s.c. three times a week for 12 weeks. Responders at 4 months received 3 MU IFN s.c. three times a week for a further 8 months. After an overnight fast, plasma or serum for the assay of DPP IV activity, IL-8, kynurenine, and tryptophan were collected at 0800 h at baseline (before starting treatment) and 2, 4, 16, and 24 weeks after starting the immunotherapy. During each of these sessions, patients completed the Montgomery Asberg Depression Rating Scale (MADRS) 5 and the Hamilton Anxiety Rating Scale. 6 DPP IV activity was determined in serum by means of a colorimetric method using the chromogenic substrate glycyl-l-proline-p-nitroanilide tosylate (Gly-Prop-NA). 29 We adapted this method for direct continuous measurement on the centrifugal analyzer Cobas Bio (Roche Diagnostics, Brussels, Belgium). The sensitivity of the assay was 3.0 U l −1 . The analytical imprecision (ie the coefficient of variation, expressed as a percentage, CV%) of the DPP IV assay was CV = 2.2%. Serum IL-8 was measured by a quantitative enzyme-linked immunosorbent assay (ELISA) (Eurogenetics, Tessenderlo, Belgium) based on appropriate and validated sets of monoclonal antibodies. The sensitivity of the assay was 2.0 pg ml −1 and the intra-assay CV value was less than 8%. Plasma tryptophan was measured by means of an HPLC as explained by us. 13 The intra-assay CV value obtained in our laboratory was 3.3%. Serum kynurenine was determined by means of HPLC as described by Holmes. 30 The intra-assay CV value for kynurenine was 4.5%. The kynurenine per tryptophan quotient (K/T) was computed. The latter estimates the activity of indoleamine 2,3 dioxygenase (IDO), the major tryptophan catabolizing enzyme, which is inducible by interferons and IL-2. 7 In order to minimize the analytical variability in the results, all blood specimens for the assays of the above parameters were performed in a single run with a single lot number of reagents and consumables employed by a single operator.
Statistics
Correlations between variables were ascertained by means of Pearson's product moment correlation coefficients. Regression analyses, which are pooled over the subjects (intra-class correlations) and which take in account the three time points, were used in order to assess time-relationships between variables. This method eliminates the inter-individual variability and assesses the relationships between the changes over time in two sets of variables. Group mean differences were checked with ANOVA. RM design ANOVAs were performed on the baseline values and the values obtained during IFN␣ immunotherapy. First we used the RM ANOVA to check the overall effects of IFN␣ on serum DPP IV and the other variables (results not shown). There were no significant differences in any of the variables either between weeks 2 and 4 or between months 4 and 6. In order to check the rapid (first month) vs protracted (several months) effects of IFN␣-based immunotherapy, we employed the nadir (DPP IV) or peak (MADRS, HAM-A, IL-8, K/T quotient) values obtained at weeks 2 and 4, and the nadir/peak values obtained at months 4 and 6 for those variables which significantly increased and decreased, respectively, during IFN␣-based immunotherapy. The results of RM design ANOVAs were corrected for sphericity. For the MADRS and HAM-A scores and DPP IV values, we examined: (i) the within-subject variability with the baseline and two treatment conditions as time factor, and (ii) two-way interactions between time × MADRS/HAM-A status. A priori comparisons between treatment means were ascertained with the Dunn test. Tests on simple effects were carried out in order to examine significant main effects or significant interaction patterns.
